Top news of the week: 18.08.2021.
Startups
Going big: Bain reels in $1.9B for more mammoth biotech bets
Bain Capital’s time in life science investing has been defined by big numbers: $720 million for its first fund, $1.1 billion for the second fund, $350 million for a single bet on Pfizer’s ...
Investors are tripping on psychedelics startups despite a murky path to commercial success
Eighteen venture capital firms have poured more than $79 million into biopharma companies developing psychedelic compounds into therapies for depression, post-traumatic stress disorder, and ...
Moderna's CEO spells out its new M&A strategy, including what the $160 billion biotech is looking for in gene editing
Moderna likely won't acquire a gene-editing company, CEO Stephane Bancel said, but would like to license in specific editing technologies.
A collaborative approach
How an expanded partnership between Veolia and MassBio has helped promote medical research in the booming Massachusetts life sciences market.
Bayer, Novartis-backed Immunitas secures $58M series B to push new checkpoint inhibitors past blockade
Immunitas is attempting to tackle the hurdles traditionally associated with checkpoint inhibitors, which don't work for everyone and typically require combination regimens with ...
FDA clears Rocket to resume testing gene therapy for a rare heart disease
The decision from the regulator ends a three-month study pause that had stalled Rocket's development of the Danon disease treatment.
Good Day BIO: Biden calls for drug price controls
Of course we’re talking about drug price controls on Friday the 13th. We have the details on what President Biden said yesterday about drug pricing, BIO’s take, and several examples of why ...
Mind Your Manners: Best Practices and Basic Etiquette in Business Development
By Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s tempting to think that the first skill you need to learn in business development is ...